This method patent covers the use of multispectral imaging combined with spectral unmixing to greatly increase the signal-to-noise level of fluorophores in a living mammal. The unmixing of tissue autofluorescence is a critical component in achieving quantitative, highly sensitive results from fluorophores in vivo.
The methodology covered by this allowance broadly covers multispectral imaging hardware and algorithm-based approaches including the use of Cambridge Research & Instrumentation (CRi’s) patented liquid crystal tunable filter technology and image acquisition and data analysis software packages.
Peter Miller, vice president and chief science officer of CRi, said: “This patent allowance further strengthens our position in the area of in vivo imaging and further validates CRi’s approach to providing customers with effective imaging solutions.”